2370 Stock Overview
Operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MEDINET Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥41.00 |
| 52 Week High | JP¥57.00 |
| 52 Week Low | JP¥37.00 |
| Beta | 0 |
| 11 Month Change | -4.65% |
| 3 Month Change | -10.87% |
| 1 Year Change | -14.58% |
| 33 Year Change | -24.07% |
| 5 Year Change | -34.92% |
| Change since IPO | -94.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2370 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | 2.5% | 7.2% | -1.1% |
| 1Y | -14.6% | -16.5% | 10.7% |
Return vs Industry: 2370 exceeded the JP Life Sciences industry which returned -16.5% over the past year.
Return vs Market: 2370 underperformed the JP Market which returned 10.7% over the past year.
Price Volatility
| 2370 volatility | |
|---|---|
| 2370 Average Weekly Movement | 6.4% |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.5% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 2370's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 2370's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | Kanenao Kubushiro | www.medinet-inc.co.jp |
MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products.
MEDINET Co., Ltd. Fundamentals Summary
| 2370 fundamental statistics | |
|---|---|
| Market cap | JP¥10.58b |
| Earnings (TTM) | -JP¥3.05b |
| Revenue (TTM) | JP¥998.00m |
0.0x
P/S Ratio0.0x
P/E RatioIs 2370 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2370 income statement (TTM) | |
|---|---|
| Revenue | JP¥998.00m |
| Cost of Revenue | JP¥668.00m |
| Gross Profit | JP¥330.00m |
| Other Expenses | JP¥3.38b |
| Earnings | -JP¥3.05b |
Last Reported Earnings
Sep 30, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 2370 perform over the long term?
See historical performance and comparison